微生態制劑預防和治療嬰幼兒濕疹的臨床觀察

摘要：目的 觀察微生態制劑預防和治療嬰幼兒濕疹的臨床價值。對確診濕疹的患兒進行治療，7 d后觀察療效是否改善，1個月后觀察復發率是否降低。方法 將2013年1月～8月我院門診確診的濕疹患兒73例隨機分為治療組（n=37）；對照組（n=36）。對照組采用丁酸氫化可的松乳膏外用聯合氯雷他定糖漿口服綜合治療。治療組則再給予培菲康口服治療。7 d后觀察兩組的臨床療效和特應性皮炎評分標準（ SCORAD 評分），1個月后統計濕疹復發率。結果 治療組的臨床療效明顯優于對照組（P<0.01）；治療組的 SCORAD 評分明顯優于對照組（P<0.01）；治療組1個月內的復發率明顯低于對照組（P<0.01）。同時，治療組的消化不良癥狀改善情況明顯優于對照組。結論 微生態制劑預防和治療嬰幼兒濕疹的臨床效果顯著，值得臨床推廣。

關鍵詞：微生態制劑；濕疹；過敏性疾病

Clinical Analysis on the Prevention and Treatment of Microecologics to Infantile Eczema

FENG Yi， CHANG Qing， CAI Yan

（Wuxi City No.8 People's Hospital， Wuxi， Jiangsu 214016， China）

Abstract：Objective： To evaluate the prevention and treatment effects of microecologics to infantile eczema. Methods： 73 children diagnosed as eczema during January to August 2013 were randomly divided into two groups. The control group were treated by Butyrate hydrocortisone cream and Loratadine syrup， while the observation group were given bifid triple viable on the basis of control group. The clinical effects and the severity scoring of atopic dermatitis（SCORAD index） of two groups were compared in 7-day's treatment. One-month eczema recurrence rate of two groups were compared. Results： The curative effect of the treatment group was better than that of the control group（P<0.01）. The SCORAD index of the treatment group decreased significantly（P<0.01）. The control group tended to have higher recurrence rate（P<0.01）. The improvement of indigestive symptom of the treatment group were better than control group（P<0.01）. Conclusion： Microecologics has a significant effect on the prevention and treatment on infantile eczema. Thus， it is worth to clinical application.

Key words：Microecologics， Eczema， Allergic disease

過敏性疾病是嬰幼兒常見的疾病之一，其患病率呈全球上升趨勢。“衛生學假說”提出兒童早期對微生物接觸減少，Th1/Th2免疫失衡是導致過敏性疾病發生的主要因素。早期患有過敏性疾病的兒童，長大后其過敏性皮炎、過敏性哮喘等過敏性疾病的發生率顯著增高[1]。對過敏性疾病的研究，主要集中在環境因素和過敏耐受方面，目前流行病學調查資料和實驗室研究認為，早期接觸微生物可以促進機體對過敏原的耐受，而口服有益菌在此方面發揮了重要的作用[2]。為此，我院對2013年1月～8月的門診濕疹患兒進行了口服益生菌的對照試驗，取得了良好的療效。……